Aims: Monitoring risk-based approaches in clinical trials are encouraged by regulatory guidance. However, the impact of a targeted source data verification (SDV) on data-management (DM) workload and on final data quality needs to be addressed.
Methods: MONITORING was a prospective study aiming at comparing full SDV (100% of data verified for all patients) and targeted SDV (only key data verified for all patients) followed by the same DM program (detecting missing data and checking consistency) on final data quality, global workload and staffing costs.
Results: In all, 137 008 data including 18 124 key data were collected for 126 patients from 6 clinical trials. Compared to the final database obtained using the full SDV monitoring process, the final database obtained using the targeted SDV monitoring process had a residual error rate of 1.47% (95% confidence interval, 1.41-1.53%) on overall data and 0.78% (95% confidence interval, 0.65-0.91%) on key data. There were nearly 4 times more queries per study with targeted SDV than with full SDV (mean ± standard deviation: 132 ± 101 vs 34 ± 26; P = .03). For a handling time of 15 minutes per query, the global workload of the targeted SDV monitoring strategy remained below that of the full SDV monitoring strategy. From 25 minutes per query it was above, increasing progressively to represent a 50% increase for 45 minutes per query.
Conclusion: Targeted SDV monitoring is accompanied by increased workload for DM, which allows to obtain a small proportion of remaining errors on key data (<1%), but may substantially increase trial costs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955406 | PMC |
| http://dx.doi.org/10.1111/bcp.14108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating gait and postural responses to subthalamic stimulation and levodopa: A prospective study using wearable technology.
Eur J Neurol
January 2025
UOC Clinica Neurologica Rete Metropolitana NEUROMET, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Background: The efficacy of subthalamic stimulation on axial signs of Parkinson's disease (PD) is debated in the literature. This study delves into the dynamic interplay of gait and posture, specifically probing their nuanced response to subthalamic stimulation and levodopa.
Methods: We used wearable sensor technology to examine alterations in the spatiotemporal parameters of gait and posture in individuals with PD before and 6 months after subthalamic deep brain stimulation (STN-DBS) surgery.
Lack of activity of HIV-1 integrase strand-transfer inhibitors on recombinase activating gene (RAG) activity at clinically relevant concentrations.
Microbiol Spectr
January 2025
Discovery Sciences and Technologies, Gilead Sciences Inc., Foster, California, USA.
Article Synopsis
- HIV-1 infection remains a major global health issue, with around 30 million individuals receiving antiretroviral treatment, where integrase strand-transfer inhibitors (INSTIs) play a key role in effective therapy.
- The research focuses on evaluating the off-target effects of clinically approved INSTIs on recombinase activating genes (RAG1 and RAG2), crucial for the immune system, using various biochemical and cellular tests.
- Results indicate that approved INSTIs have minimal to no adverse effects on RAG activity and V(D)J recombination, supporting their continued use in HIV-1 treatment without significant immune system concerns.
Measuring the diagnostic management and follow-up imaging for glioma patients across Belgian hospitals between 2016 and 2019.
Cancer Med
November 2024
Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
Objectives: This study aimed to assess the diagnostic management and follow-up imaging for glioma patients across Belgian hospitals by calculating process indicators.
Methods: Patients with newly diagnosed glioma in Belgium (2016-2019) were selected from the Belgian Cancer Registry. The National Social Security Number served as unique patient identifier, linking the Registry to vital status and reimbursement data.
Bacillus thuringiensis Cry14A family proteins as novel anthelmintics against gastrointestinal nematode parasites.
PLoS Negl Trop Dis
October 2024
Program in Molecular Medicine, UMASS Chan Medical School, Worcester, Massachusetts, United States of America.
Article Synopsis
- - Bacillus thuringiensis (Bt) Cry proteins, like Cry14Ab, have been used in transgenic crops for insect pest control and now show promise against nematodes, particularly the soybean cyst nematode
- - Recent studies indicate that Cry14Ab effectively targets various gastrointestinal nematode parasites both in laboratory settings (in vitro) and in live animals (in vivo)
- - A related protein, Cry14Ac, was identified and shown to be effective against certain nematodes, demonstrating potential for further development as an anthelmintic treatment
Consensus-driven target product profiles for curative sickle cell disease gene therapies.
Mol Ther Methods Clin Dev
September 2024
Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20814, USA.
Therapeutic innovation to address sickle cell disease (SCD) is at a historical apex, characterized by a drug discovery, development, and commercialization landscape that includes potentially curative gene therapies. Given the wide geographic distribution of SCD, with a major presence in Africa, it is imperative that new medicines are designed to meet the specific needs of persons with SCD everywhere. Target product profiles (TPPs) detail the desired attributes of new medicines and serve as a guide for drug developers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!